Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on March 30, 2021, primarily announcing a CFO transition. Howard Liang, Ph.D., the current Chief Financial Officer and Chief Strategy Officer, will retire effective June 30, 2021. His departure is amicable and not due to any disagreements concerning financial reporting or policies. The company has appointed Julia Wang as the new Chief Financial Officer, also effective June 30, 2021. Ms. Wang brings extensive financial leadership experience, having previously held senior roles at Alexion Pharmaceuticals, Quest Diagnostics, and Johnson & Johnson, including CFO positions for J&J's pharmaceutical business in China. She has been with BeOne Medicines since June 2020 as Senior Vice President, Enterprise Optimization and Deputy Chief Financial Officer, ensuring a smooth handover. Angus Grant, Ph.D., Chief Business Executive, will assume oversight of the strategy function during this transition.
Key Highlights
- 1Howard Liang, Ph.D. to retire as CFO and CSO effective June 30, 2021.
- 2Howard Liang's retirement is not due to any disagreement on financial matters.
- 3Julia Wang appointed as new Chief Financial Officer, effective June 30, 2021.
- 4Julia Wang has a strong background in financial leadership from major pharmaceutical and healthcare companies.
- 5Ms. Wang has been with BeOne Medicines since June 2020, facilitating a smooth transition.
- 6Angus Grant, Ph.D. will oversee the strategy function during the transition.
- 7The company issued a press release on March 30, 2021, to announce these changes.